2nd Quarter - Amendment
THE MCMANUS GROUP for DENDREON PHARMACEUTICALS LLC
Firm
Client
Income
$30,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 15, 2020 | $30,000 | Replaced |
| 2nd Quarter - Amendment | Aug 6, 2020 | $30,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Jan 11, 2022 | $30,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act. Coronavirus relief waivers.
Foreign entity interest: Dendreon is a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | LA, Bill Thomas. Staff Director, W&M Health Subcommittee |
| ALANNA TEMME | LD, Rep. Jon Porter |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.